SSY Group (HKG:2005) obtained production and registration approval for two products from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.
The approvals are for Levofloxacin Eye Drops used to treat blepharitis, meibomianitis, dacryocystitis, and conjunctivitis among other illnesses, and Compound Sodium Picosulfate Granules used in bowel cleansing preparation before colonoscopy, X-ray, and surgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments